KH-001
Premature Ejaculation
Phase 1Active
Key Facts
About Kadence Bio
Kadence Bio is a private, clinical-stage therapeutics company founded in 2020, developing small molecule drugs for sexual and mental health. Its lead asset, KH-001, is an on-demand oral treatment for premature ejaculation (PE) and has successfully completed Phase 1 safety studies as of Q3 2024. The company positions itself to address a significant intimacy gap and unmet medical need, as there are currently no FDA-approved pharmacological treatments for PE. Kadence Bio is a certified B-Corp and has participated in several accelerator programs, indicating a focus on social impact and venture backing.
View full company profile